Hypertrophic Cardiomyopathy Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Mavacamten: A Novel Agent for Hypertrophic Cardiomyopathy
Clin Ther. 2024 Mar 19:S0149-2918(24)00062-6. doi: 10.1016/j.clinthera.2024.02.007. Online ahead of print.ABSTRACTPURPOSE: Hypertrophic cardiomyopathy (HCM) is an under-recognized genetic cardiac disorder affecting the muscles and contractility of the heart, which in turn can result in heart failure symptoms, arrhythmia, and sudden cardiac death. Previously, pharmacotherapy options for HCM were not disease-specific, often poorly tolerated, and overall inadequate for optimal management. This narrative review discusses the pharmacology of the novel drug mavacamten, the clinical trials supporting its use, and considerations f...
Source: Clinical Therapeutics - March 20, 2024 Category: Drugs & Pharmacology Authors: J Chase Cole Samantha F Benvie Marci DeLosSantos Source Type: research

Left ventricular hypertrophy. Is there only hypertrophic cardiomyopathy?
Arch Cardiol Mex. 2024;94(1):123-126. doi: 10.24875/ACM.22000266.NO ABSTRACTPMID:38507316 | DOI:10.24875/ACM.22000266 (Source: Archivos de Cardiologia de Mexico)
Source: Archivos de Cardiologia de Mexico - March 20, 2024 Category: Cardiology Authors: Carmen Lluch-Requerey Miguel A Montilla-Garrido Jos é I Morgado-García-Polavieja Álvaro Gragera-Martínez Antonio G ómez-Menchero Source Type: research

Response to: Regard to assessing agreement between two raters with kappa statistics
We thank Dr. Yu et al. for their interest in our manuscript. As the authors state, there are a variety of statistical methods that may be used to assess inter-operator agreement – in this case between the Risk-SCD and ACC/AHA scores used to stratify risk of sudden cardiac arrest in hypertrophic cardiomyopathy (HCM) [1]. (Source: International Journal of Cardiology)
Source: International Journal of Cardiology - March 19, 2024 Category: Cardiology Authors: Elizabeth D. Paratz, Dion Stub, Nigel Sutherland, Sarah Gutman, Andre La Gerche, Justin Mariani, Andrew Taylor, Andris Ellims Source Type: research

A case of hypertrophic cardiomyopathy with previous aortic valve replacement
We describe a 45-year-old patient who was diagnosed with hypertrophic obstructive cardiomyopathy (HOCM) after the aortic valve replacement surgery. Enlarged left atria, thickened ventricular septum, left ventr... (Source: Journal of Cardiothoracic Surgery)
Source: Journal of Cardiothoracic Surgery - March 19, 2024 Category: Cardiovascular & Thoracic Surgery Authors: Hongyan Xiao, Laichun Song, Meng Guo and Liang Tao Tags: Case Report Source Type: research

Role of experience in Myectomy for hypertrophic cardiomyopathy: With very high procedural volume, Myectomy remains low-risk even with concomitant procedure need
Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiomyopathy, affecting an estimated 1/200 to 1/500 people. [1] Dynamic left ventricular outflow tract (LVOT) is present in the majority of patients with HCM, either at rest or with provocation. Dynamic LVOT obstruction is a major cause of symptoms, is associated with worse outcomes, and remains the primary therapeutic target in the treatment of obstructive HCM. [2] In patients with medically refractory symptoms related to dynamic LVOT obstruction, advanced therapies, including septal reduction therapy (SRT), are recommended. (Source: International Journal of Cardiology)
Source: International Journal of Cardiology - March 16, 2024 Category: Cardiology Authors: Jeffrey B. Geske, Hartzell V. Schaff Source Type: research

Post-hoc standardisation of parametric T1 maps in cardiovascular magnetic resonance imaging: a proof-of-concept
This study was supported by the BMBF / DZHK.PMID:38490103 | DOI:10.1016/j.ebiom.2024.105055 (Source: Nuklearmedizin)
Source: Nuklearmedizin - March 15, 2024 Category: Radiology Authors: Darian Viezzer Thomas Hadler Jan Gr öschel Clemens Ammann Edyta Blaszczyk Christoph Kolbitsch Simone Hufnagel Riccardo Kranzusch-Gro ß Steffen Lange Jeanette Schulz-Menger Source Type: research

A rare homozygous mutation in the YARS2 gene presents with hypertrophic cardiomyopathy, lactic acidosis and anemia in a Chinese infant
Gene. 2024 Mar 13:148379. doi: 10.1016/j.gene.2024.148379. Online ahead of print.NO ABSTRACTPMID:38490507 | DOI:10.1016/j.gene.2024.148379 (Source: Gene)
Source: Gene - March 15, 2024 Category: Genetics & Stem Cells Authors: Dandan Xiang Kangkang Xu Mei Chen Zhongman Zhang Ningning Sun Yuying Qi Jie Lu Chunli Wang Shiwei Yang Source Type: research